Because of the potential for adverse effects on a nursing baby, use during breastfeeding is usually not recommended unless the expected benefit to the mother clearly outweighs any possible risk to the child
Essentially, it will help with glucose control by helping the pancreas release the correct amount of insulin when carbs are present in the body
At InjectCo, the BriteBody program runs $425 per month, so three months through the program totals $1,275
What stood out: CagriSema achieved 23.0% weight loss at 84 weeks (efficacy estimand) Tirzepatide achieved 25.5% On the treatment-regimen estimand, weight loss was 20.2% vs 23.6% Primary endpoint not met: CagriSema did not demonstrate non-inferiority vs tirzepatide on weight loss at 84 weeks Why this matters This is a reminder that in obesity pharmacotherapy, very effective and best-in-class are not the same conversation
Troubleshooting Having some issues
Compounded semaglutide can be used for managing chronic weight in obese (BMI of 30 or greater) and overweight (BMI of 27 or greater with at least one other weight-related condition) adults and type 2 diabetes, when used in combination with exercise and a reduced-calorie diet
